

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.

These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.

Some data have been adjusted to facilitate estimates of standard indicators across countries.

Details of the process for searching, grading and including data, along with their interpretation, are detailed in:

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

For more information on the Reference Group, please go to: www.IDURefGroup.Com

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
1. Needle and syringe programs (NSPs)	5
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
2. Opioid substitution programs (OST)	10
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
3. Other Drug Treatment (ODT)	25
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
4. HIV testing and counselling (T&C)	41
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
5. Anti-retro-viral (ARV) treatment	45
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
6. Condoms	48
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

Iran, Islamic Republic (South Asia)

Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	0.29	0.40	0.52
Year of IDU prevalence estimate	2004		
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	5	15	25
Year of HIV prevalence among IDU estimate	2005		
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	51 799 449 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	152 000	207 000	270 500
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	7600	31 050	67 625

1. Needle and syringe programs (NSPs)

NSP 1: Availability of NSPs

Are NSPs available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other NSP indicators
When were NSPs first introduced?	2003
Reference	Vazirian, M., B. Nassirimanesh, et al. (2005). "Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study." <i>Harm Reduction Journal</i> 2(1): 19.
Are needles and syringes available for purchase from pharmacies?	Yes
Most recent year of documentation	2008
Reference	Cook, C. and N. Kanaef (2008). <i>Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics</i> . London, International Harm Reduction Association.,

NSP 2: Number of NSP sites

Data reported	428 NSP sites 637 NSP sites		
Year of reported data	2009		
Reference	Mostashari, G. (Drug Demand Reduction Senior Expert), UNODC. Response to "Iran - UN Reference Group - Final Data Check". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV & injecting drug use on 13 October 2009. WHO, UNAIDS., et al. (2009). <i>Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009</i> . Geneva, WHO.		
Adjustments	Figures taken as range		
Final/Adjusted data (to be used as indicator numerator)	428 - 637		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	52 747 616 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	155 000	210 500	275 000
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	1.56	2.53	4.11

NSP 3: Number of pharmacy sites where needles and syringes are available for purchase

Data reported	Needles and syringes available for purchase from pharmacies but number of sites not available		
Year of reported data	2008		
Reference	Cook, C. and N. Kanaef (2008). Global state of harm reduction 2008: Mapping the response to drug related HIV and hepatitis C epidemics. London, International Harm Reduction Association,.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	2004		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

NSP 4: Total number of sites where needles and syringes are available

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data	(source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	55000 IDUs accessed NSPs once per month or more in past 12 months		
Year of reported data	2006		
Reference	Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009. Eastern Mediterranean Regional Office of the World Health Organization (2009). Questionnaire survey on viral hepatitis diagnosis, treatment and vaccination for injecting drug users - Iran.		
Adjustments	Assumed this is the total number of clients accessing NSP at anytime in last 12 months		
Final/Adjusted data (to be used as indicator numerator)	55 000		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	49 649 984 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	146 000	198 000	259 000
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	21.2	27.8	37.7

NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	55000 IDUs accessed NSPs once per month or more in past 12 months		
Year of reported data	2006		
Reference	Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009. Eastern Mediterranean Regional Office of the World Health Organization (2009). Questionnaire survey on viral hepatitis diagnosis, treatment and vaccination for injecting drug users - Iran.		
Adjustments	Assumed count is occasions of service		
Final/Adjusted data (to be used as indicator numerator)	55 000		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	49 649 984 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	146 000	198 000	259 000
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	0.21	0.28	0.38

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

Data reported	8 504 651 syringes distributed		
Year of reported data	2008		
Reference	World Health Organisation (2009). Universal Access Unpublished Data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	8 504 651		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU	Low	Mid	High
	31.44	41.1	55.95

NSP: All documents reviewed

Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting drug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).

Canadian HIV/AIDS Legal Network (2006). Prison needle exchange: Lessons from a comprehensive review of international evidence and

Country coordinating mechanism - Iran (2008). Scaling up HIV/AIDS prevention programs towards universal access with increasing the partnership of non government sector. Tehran: 74.

Eastern Mediterranean Regional Office of the World Health Organization (2009). Questionnaire survey on viral hepatitis diagnosis, treatment and vaccination for injecting drug users - Iran.

International Harm Reduction Association (2008). Harm Reduction and Human Rights: The Global Response to Injection-Driven HIV Epidemics:

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Jurgens, R. (2007). Interventions to address HIV in prisons: needle and syringe programmes and decontamination strategies. Geneva, World Health Organisation (WHO).

Jurgens, R. and G. Betteridge (2005). "Prisoners who inject drugs: public health and human rights imperatives." *Health & Human Rights* 8(2): 46-

Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and harm reduction programs, Development Oriented Drug Control Program GTZ Eschborn: 179.

Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and Harm Reduction Programs, Development Oriented Drug Control Program.

Mojtahedzadeh, V., N. Razani, et al. (2008). "Injection drug use in Rural Iran: integrating HIV prevention into Iran's rural primary health care system." *AIDS & Behavior* 12(Suppl 2): S7-12.

Monitoring AIDS Pandemic (MAP) Network (2004). AIDS in Asia: face the facts. A comprehensive analysis of the AIDS epidemics in Asia, Monitoring AIDS Pandemic (MAP) Network.

Needle, R., D. Burrows, et al. (2005). "Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users." *International Journal of Drug Policy* 16(Supplement 1): S45-S57.

Nissaramanesh, B., M. Trace, et al. (2005). The rise of harm reduction in the Islamic Republic of Iran. The Beckley Foundation Drug Policy Programme: A drugscope briefing paper.

Razani, N., M. Mohraz, et al. (2007). "HIV risk behavior among injection drug users in Tehran, Iran." *Addiction* 102(9): 1472-82.

Rossi, D., S. Harris, et al. (2009). The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs". Open Society Institute – International Harm Reduction Development Program. New York.

Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on

Todd, C. S., B. Nassiramanesh, et al. (2007). "Emerging HIV epidemics in Muslim countries: assessment of different cultural responses to harm reduction and implications for HIV control." *Current HIV/AIDS Reports* 4(4): 151-7.

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Central Asia". Tehran.

UNODC (2008). Harm Reduction Programmes in I.R. of Iran.

USAID, UNAIDS, et al. (2005). Coverage of essential HIV/AIDS services - National questionnaire.

Vazirian, M., B. Nassiramanesh, et al. (2005). "Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study." *Harm Reduction Journal* 2(1): 19.

WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.

WHO, UNAIDS, et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

World Health Organisation (WHO) Regional Office for the Eastern Mediterranean (2005). Progress report on HIV/AIDS and the 3 by 5 initiative, World Health Organisation (WHO) Regional Office for the Eastern Mediterranean.

Zamani, S., M. Kihara, et al. (2006). "High Prevalence of HIV Infection Associated With Incarceration Among Community-Based Injecting Drug Users in Tehran, Iran." *JAIDS* 42(3): 342.

2. Opioid substitution treatment (OST)**OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was agonist OST first available?	2003
Reference	Mokri, A. and M. Vazirian (2005). Effectiveness of methadone maintenance program in reducing illicit drug use and HIV related high-risk behavior: A multi-center study. Tehran.

OST 2: Availability of methadone maintenance treatment (MMT)

Is MMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was MMT first available?	
Reference	

OST 3: Availability of buprenorphine maintenance treatment (BMT)

Is BMT available?	Yes
Comments	
Most recent year of documentation	2009
Reference	See references for other OST indicators
When was BMT first available?	
Reference	

OST 4: Availability of other forms of agonist OST

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	80-140mg
Comments	Average daily maintenance dose
Year	2008
Reference	WHO regional office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran.
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	7mg
Comments	Average daily dose from pilot program
Year	2007
Reference	Mokri, A., R. Farnam, et al. (2007). Establishing private service office-based buprenorphine maintenance treatment in Iran: the preliminary results [C6-4 (436)]. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

OST 7: Total number of all sites providing OST

Data reported	680 OST sites 1100 MMT sites (all MMT sites are able to provide BMT but only a subset of them currently offer this) 10 BMT sites in pilot study		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO. Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009. Mokri, A., R. Farnam, et al. (2007). Establishing private service office-based buprenorphine maintenance treatment in Iran: the preliminary results [C6-4 (436)]. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA)..		
Adjustments	Figures taken as range Assume that all BMT sites are located with MMT sites		
Final/Adjusted data (to be used as indicator numerator)	680 - 1100		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	2.51	4.30	7.24

OST 8: Number of sites providing MMT

Data reported	1100 MMT sites (all MMT sites are able to provide BMT but only a subset of them currently offer this)		
Year of reported data	2008		
Reference	Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1100		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	4.07	5.31	7.24

OST 9: Number of sites providing BMT

Data reported	10 BMT sites in pilot study All MMT sites are able to provide BMT but only a subset of them currently offer this		
Year of reported data	2005		
Reference	Mokri, A., R. Farnam, et al. (2007). Establishing private service office-based buprenorphine maintenance treatment in Iran: the preliminary results [C6-4 (436)]. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),. Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	10		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	48 523 728 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	142 500	193 500	253 000
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	0.04	0.05	0.07

OST 10: Number of sites providing other forms of agonist OST

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of sites providing other forms of OST per 1000 IDUs	Low	Mid	High

OST 11: Number of all clients in any OST at a single point in time

Data reported	OST available but number of clients on OST not known		
Year of reported data	2008		
Reference	<p>Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.</p> <p>Mokri, A., R. Farnam, et al. (2007). Establishing private service office-based buprenorphine maintenance treatment in Iran: the preliminary results [C6-4 (436)]. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 12: Number of all clients in MMT at a single point in time

Data reported	MMT available but number of clients not known		
Year of reported data	2008		
Reference	<p>Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment.</p> <p>Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 13: Number of all clients in BMT at a single point in time

Data reported	BMT available but number of clients not known		
Year of reported data	2005		
Reference	<p>Mokri, A., R. Farnam, et al. (2007). Establishing private service office-based buprenorphine maintenance treatment in Iran: the preliminary results [C6-4 (436)]. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association (IHRA),.</p> <p>Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.</p>		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	<p>Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.</p> <p>Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.</p>		
General population 15-64 years of age at year of reported data	48 523 728 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	142 500	193 500	253 000
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

OST 14: Number of all clients in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High

OST 15: Number of IDUs in any OST at a single point in time

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment. Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs in OST at a single point in time	Low	Mid	High
	NK	NK	NK

OST 16: Number of IDUs in MMT at a single point in time

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs in MMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 17: Number of IDUs in BMT at a single point in time

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2008		
Reference	Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

OST 18: Number of IDUs in other forms of OST at a single point in time

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High

OST 19: Number of all clients receiving any OST in a 12 month period

Data reported	10 2000 clients in MMT 6000 clients in BMT		
Year of reported data	2008		
Reference	Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment. Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments	Assumed mutually exclusive Assuming figures correct for same time period Assumed individual clients		
Final/Adjusted data (to be used as indicator numerator)	108 000		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs	Low	Mid	High
	39.93	52.17	71.05

OST 20: Number of all clients receiving MMT in a 12 month period

Data reported	10 2000 clients in MMT		
Year of reported data	2008		
Reference	Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment.		
Adjustments	Assumed individual clients		
Final/Adjusted data (to be used as indicator numerator)	102 000		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs	Low	Mid	High
	37.71	49.28	67.11

OST 21: Number of all clients receiving BMT in a 12 month period

Data reported	6000 clients in BMT		
Year of reported data	2008		
Reference	Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments	Assumed individual clients		
Final/Adjusted data (to be used as indicator numerator)	6000		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	2.22	2.90	3.95

OST 22: Number of all clients receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High

OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment. Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Drug Control Headquarters Iran (2009). Drug control in 2008: Annual report & rapid situation assessment.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 25: Number of IDUs receiving BMT in a 12 month period

Data reported	BMT available but number of IDUs receiving BMT not known		
Year of reported data	2008		
Reference	Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on 14 May 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

OST 26: Number of IDUs receiving other forms of OST in a 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High

OST: All documents reviewed

- Country coordinating mechanism - Iran (2008). Scaling up HIV/AIDS prevention programs towards universal access with increasing the partnership of non government sector. Tehran: 74.
- Eastern Mediterranean Regional Office of the World Health Organization (2009). Questionnaire survey on viral hepatitis diagnosis, treatment and vaccination for injecting drug users - Iran.
- Farnia, M., A. Sedaghat, et al. (2008). Decrease in prevalence of HIV in prisoners with drug-use related crimes in Islamic Republic of Iran following scaling up of a comprehensive HIV prevention package.
- International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.
- Jurgens, R. (2007). Interventions to address HIV in prisons: drug dependence treatments. Evidence for action technical papers. Geneva, World Health Organisation (WHO).
- Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and harm reduction programs, Development Oriented Drug Control Program GTZ Eschborn: 179.
- Mojtahedzadeh, V., N. Razani, et al. (2008). "Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system." *AIDS & Behavior* 12(Supp 2): S7-12.
- Mokri, A., R. Farnam, et al. (2007). Establishing private service office-based buprenorphine maintenance treatment in Iran: the preliminary results [C6-4 (436)]. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland, International Harm Reduction Association
- Nissaramanesh, B., M. Trace, et al. (2005). The rise of harm reduction in the islamic republic of Iran. The beckley foundation drug policy programme: A drugscope briefing paper.
- Razani, N., M. Mohraz, et al. (2007). "HIV risk behavior among injection drug users in Tehran, Iran." *Addiction* 102(9): 1472-82.
- Rossi, D., S. Harris, et al. (2009). The impacts of the Drug War in Latin America and the Caribbean. At what cost? HIV and human rights consequences of the global "war on drugs". Open Society Institute – International Harm Reduction Development Program. New York.
- Taj, M. (HIV/AIDS National Programme Officer), UNODC. Personal Communication: Response to the "UN HIV and IDU Reference Group: Request to fill data gaps - the Islamic Republic of Iran". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV and Injecting Drug Use on
- Todd, C. S., B. Nassiramanesh, et al. (2007). "Emerging HIV epidemics in Muslim countries: assessment of different cultural responses to harm reduction and implications for HIV control." *Current HIV/AIDS Reports* 4(4): 151-7.
- United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.
- UNODC (2008). Harm Reduction Programmes in I.R. of Iran.
- USAID, UNAIDS, et al. (2005). Coverage of essential HIV/AIDS services - National questionnaire.
- Vazirian, M., B. Nassirimanesh, et al. (2005). "Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study." *Harm Reduction Journal* 2(1): 19.
- WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.
- World Health Organisation (WHO) Regional Office for the Eastern Mediterranean (2005). Progress report on HIV/AIDS and the 3 by 5 initiative, World Health Organisation (WHO) Regional Office for the Eastern Mediterranean.
- World Health Organization (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health
- Zamani, S. (2008). Methadone maintenance treatment (MMT) for drug-using prisoners in Ghezel Hesar Prison, Karaj, Iran.
- Zamani, S., G. Mostashari, et al. (2009). "A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran." *International Journal of Drug Policy*.
- Zamani, S., M. Kihara, et al. (2006). "High Prevalence of HIV Infection Associated With Incarceration Among Community-Based Injecting Drug Users in Tehran, Iran." *JAIDS* 42(3): 342.

3. Other drug treatment (ODT)**ODT 1 - Detoxification****ODT 1.1: Number of sites providing detoxification**

Is detoxification available?	Yes		
Number of sites - data reported	450 detoxification centres		
Year of reported data	2008		
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	450		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	1.66	2.17	2.96

ODT 1.2: Number of IDUs receiving detoxification

Data reported	Detoxification available but number not known		
Year of reported data	2008		
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs in detoxification in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in detoxification at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time

Data reported	25000 clients in detoxification		
Year of reported data	2008		
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	25 000		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs	Low	Mid	High
	0.09	0.12	0.16
INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 2 - Residential rehabilitation

ODT 2.1: Number of sites providing residential rehabilitation

Is residential rehabilitation present?	Yes		
Number of sites - data reported	31 therapeutic communities		
Year of reported data	2008		
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	31		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	0.11	0.15	0.20

ODT 2.2: Number of IDUs in residential rehabilitation

Data reported	Residential rehabilitation present but number not known		
Year of reported data	2008		
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 2.3: Number of all clients in residential rehabilitation

Data reported	2649 clients in Therapeutic communities		
Year of reported data	2007		
Reference	United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	2649		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	50 752 349 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	149 000	202 500	265 000
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	0.01	0.01	0.02
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High

ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period	Low	Mid	High
INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time	Low	Mid	High

ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs	Low	Mid	High
INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs	Low	Mid	High

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	14 316 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	14 316		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	52.92	69.16	94.18

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 4.3: Number of all clients in peer-based support groups

Data reported	Narcotics Anonymous present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs	Low	Mid	High
	NK	null	null

ODT 5 - Drug treatment (treatment type not specified)

ODT 5.1: Number of drug treatment sites (treatment type not specified)

Type of drug treatment available	Unspecified		
Number of sites - data reported	653 sites		
Year of reported data	2007		
Reference	United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.		
Adjustments	Assumed counts are mutually exclusive		
Final/Adjusted data (to be used as indicator numerator)	653		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	50 752 349 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	149 000	202 500	265 000
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	2.46	3.22	4.38

ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)

Data reported	Drug treatment available but number of IDUs in treatment not known		
Year of reported data	2007		
Reference	United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	50 752 349 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	149 000	202 500	265 000
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 5.3: Number of all clients in drug treatment (treatment type not specified)

Data reported	28 693 clients treated at government operated outpatient sites 190 464 clients treated at private outpatient sites 11 944 clients treated at private inpatient sites		
Year of reported data	2007		
Reference	United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	231 101		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	50 752 349 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	149 000	202 500	265 000
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	0.87	1.14	1.55
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 6 - Drug treatment in prisons

ODT 6.1: Number of prison drug treatment sites

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

ODT 6.2: Number of IDUs in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 6.3: Number of all clients in drug treatment in prisons

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported	Temporary compulsory drug treatment centers exist or have existed but number not known		
Year of reported data	2009		
Reference	Jahani, M., P. Kheirandish, et al. (2009). "HIV seroconversion among injection drug users in detention, Tehran, Iran." AIDS 23(4): 538.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	52 747 616 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	155 000	210 500	275 000
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported	Temporary compulsory drug treatment centers exist or have existed but number not known		
Year of reported data	2009		
Reference	Jahani, M., P. Kheirandish, et al. (2009). "HIV seroconversion among injection drug users in detention, Tehran, Iran." AIDS 23(4): 538.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	52 747 616 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	155 000	210 500	275 000
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported	Temporary compulsory drug treatment centers exist or have existed but number not known		
Year of reported data	2009		
Reference	Jahani, M., P. Kheirandish, et al. (2009). "HIV seroconversion among injection drug users in detention, Tehran, Iran." AIDS 23(4): 538.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	52 747 616 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	155 000	210 500	275 000
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	

ODT: All documents reviewed

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

Jahani, M., P. Kheirandish, et al. (2009). "HIV seroconversion among injection drug users in detention, Tehran, Iran." *AIDS* 23(4): 538.

Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and Harm Reduction Programs, Development Oriented Drug Control Program.

Mojtahedzadeh, V., N. Razani, et al. (2008). "Injection drug use in Rural Iran: integrating HIV prevention into iran's rural primary health care system." *AIDS & Behavior* 12(Supp 2): S7-12.

Needle, R., D. Burrows, et al. (2005). "Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users." *International Journal of Drug Policy* 16(Supplement 1): S45-S57.

Nissaramanesh, B., M. Trace, et al. (2005). The rise of harm reduction in the islamic republic of Iran. The beckley foundation drug policy programme: A drugscope briefing paper.

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.

USAID, UNAIDS, et al. (2005). Coverage of essential HIV/AIDS services - National questionnaire.

WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.

World Health Organization (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health

4. HIV testing and counselling (T&C)

T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2008
Reference	See references for other VCT indicators

T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported	VCT provided by: 124 triangular clinics 31 VCT centres funded by MOH 20 VCT clinics funded by Red Crescent		
Year of reported data	2008		
Reference	WHO regional office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Mostashari, G. (Drug Demand Reduction Senior Expert), UNODC. Personal Communication: Response to "Iran - UN Reference Group - Final Data Check". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV & injecting drug use on 13 October 2009.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	175		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	0.65	0.85	1.15

T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	VCT available but number not known		
Year of reported data	2008		
Reference	WHO regional office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	0	0	0
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High

T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result

Year of reported data	2007
Reference	UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362. WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.
Data reported for both male and female IDUs	23% IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	23.00%
Data reported for male IDUs	23% male IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	23.00%
Data reported for female IDUs	16% female IDUs received an HIV test in the last 12 months and know their results
Adjustments	
Final/Adjusted data	16.00%

T&C: All documents reviewed

Country coordinating mechanism - Iran (2008). Scaling up HIV/AIDS prevention programs towards universal access with increasing the partnership of non government sector. Tehran: 74.

Knoess, J. (2006). HIV/AIDS and Intravenous Drug Use in Asia: A mapping of existing HIV/AIDS and Harm Reduction Programs, Development Oriented Drug Control Program.

Mostashari, G. (Drug Demand Reduction Senior Expert), UNODC. Personal Communication: Response to "Iran - UN Reference Group - Final Data Check". Tehran, Iran, 2009. Received by the Reference Group to the UN on HIV & injecting drug use on 13 October 2009.

National AIDS Committee Secretariat Ministry of Health and Medical Education (2008). Islamic Republic of Iran country report on monitoring of the United Nations General Assembly Special Session on HIV and AIDS.

UNAIDS (2008). Report on the global AIDS epidemic. Geneva, UNAIDS: 362.

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Central Asia". Tehran.

WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

5. Anti-retro-viral (ARV) treatment**ARV 1: Number of sites providing ARV treatment**

Data reported	86 sites		
Year of reported data	2008		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	86		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
HIV among IDU prevalence estimate (%)	Low	Mid	High
	5	15	25
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)	Low	Mid	High
	7600	31 050	67 625
INDICATOR: Number of ARV treatment sites per 1000 IDUs	Low	Mid	High
	0.32	0.42	0.57
INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV	Low	Mid	High
	1.27	2.77	11.32

ARV 2: Number of IDUs receiving ARVs at a single point in time

Data reported	829 people on ARVs it is estimated that 70% of those receiving ARVs are current or former drug users		
Year of reported data	2007		
Reference	National AIDS Committee Secretariat Ministry of Health and Medical Education (2008). Islamic Republic of Iran country report on monitoring of the United Nations General Assembly Special Session on HIV and AIDS.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	580		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	50 752 349 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	149 000	202 500	265 000
HIV among IDU prevalence estimate (%)	Low	Mid	High
	5	15	25
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.		
Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	7450	30 375	66 250
INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV	Low	Mid	High
	0.88	1.91	7.79

ARV 3: Restrictions on IDUs' access to ARVs

Do restrictions exist which limit IDUs' access to ARV treatment?	No restrictions
Year of reported data	2005
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34. Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting rug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).

ARV: All documents reviewed

Aceijas, C., E. Oppenheimer, et al. (2006). "Antiretroviral treatment for injecting drug users in developing and transitional countries 1 year before the end of the "Treating 3 million by 2005. Making it happen. The WHO strategy" ("3 by 5")." *Addiction* 101(9): 1246-53.

Asian Harm Reduction Network (AHRN) (2004). Scaling up provision of anti-retrovirals to injecting rug users and non-injecting drug users in Asia: World Health Organization "3 x 5" initiative, Asian Harm Reduction Network (AHRN).

International Harm Reduction Association (IHRA) (2007). Conference abstracts book. 18th International Conference on the Reduction of Drug Related Harm, Warsaw, Poland.

National AIDS Committee Secretariat Ministry of Health and Medical Education (2008). Islamic Republic of Iran country report on monitoring of the United Nations General Assembly Special Session on HIV and AIDS.

WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

6. Condoms**Condoms 1: Availability of condom programs targeting IDUs**

Are condom programs targeting IDUs available?	Yes
Comments	
Year	2008
Reference	See references for other Condom indicators

Condoms 2: Number of sites distributing condoms to IDUs

Data reported	Condoms available at NSP sites 654 NSP sites in the country		
Year of reported data	2009		
Reference	WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34. United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran. Eastern Mediterranean Regional Office of the World Health Organization (2009). Questionnaire survey on viral hepatitis diagnosis, treatment and vaccination for injecting drug users - Iran.		
Adjustments	Assumed all NSPs provide condoms		
Final/Adjusted data (to be used as indicator numerator)	654		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	52 747 616 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	155 000	210 500	275 000
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	2.38	3.11	4.22

Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High

Condoms 4: Number of condoms distributed to IDUs

Data reported	764 364 condoms distributed from 211 sites targeting IDUs operated by the Iranian State Welfare Organisation in 2007		
Year of reported data	2008		
Reference	United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.		
Adjustments	For lower bound use data from sites reporting only For upper bound assumed average distribution from these 211 sites in 2007 is the same as the average distribution for all 654 sites in 2008		
Final/Adjusted data (to be used as indicator numerator)	764 364 - 2 369 166		
IDU prevalence estimate (%)	Low	Mid	High
	0.29	0.40	0.52
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745. Upper and lower bounds of range are estimates only, these were calculated as per the methods outlined in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	51 799 449 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	152 000	207 000	270 500
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	2.83	7.57	15.59

Condoms: All documents reviewed

United Nations Office on Drugs and Crime Office of the I.R. of Iran and Presidency Drug Control Headquarters (2008). Report - Regional seminar on "Reducing harms of drug use in Middle East, West and Centrak Asia". Tehran.

USAID, UNAIDS, et al. (2005). Coverage of essential HIV/AIDS services - National questionnaire.

Vazirian, M., B. Nassirimanesh, et al. (2005). "Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study." *Harm Reduction Journal* 2(1): 19.

WHO Regional Office for the Eastern Mediterranean (2008). HIV prevention and care among injecting drug users in the Islamic Republic of Iran. Cairo, World Health Organization: 34.